Leukocare AG. (6/30/22). "Press Release: Leukocare Announces New Management Structure to Support Global Set-up and Accelerate Growth". Martinsried.

	Organisation	Leukocare AG
	Group	Leukocare (Group)
	Organisation 2	Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY)
	Group	Formycon (Group)
	Product	biopharmaceutical development services
	Product 2	drug delivery technology (drug formulation technology)
	Person	Scholl, Michael (Leukocare AG 201105 CEO)
	Person 2	Hauck, Sabine (Thermosome 202406– CTO before Leukocare + Medigene + Idea)

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board consists of Michael Scholl, Chief Executive Officer (CEO), and Dr. Georg Dönges, Chief Financial Officer (CFO), both remaining in their established roles, as well as Dr. Cornelius Pompe, former Vice President, Head of R&D, taking up the newly created position of Chief Development Officer (CDO), and Dr. Dirk Winnemöller, former Vice President, Head of Commercial, taking up the newly created position of Chief Business Officer (CBO). In addition to the newly established roles in the Executive Board, Dr. Sabine Hauck steps up to Executive Vice President, Corporate Development, and Dr. Andreas Geissler becomes Executive Vice President, IP and Legal. Dr. Andreas Seidl, former Chief Operating Officer (COO) of Leukocare, will leave his executive role to become CSO of Formycon AG, but will actively stay involved in Leukocare by taking up the newly created position as Chairman of the Scientific Advisory Board of Leukocare.

Michael Scholl, CEO at Leukocare, said, “This new management structure is key to our growth strategy and will enable us to further leverage our potential as global innovator for drug product development. I am therefore very much looking forward to collaborating with my colleagues from the Executive Board. Being renowned experts in their respective core businesses, Leukocare will greatly benefit from their multifaceted skill set. Moreover, I would like to take this opportunity to thank Andreas Seidl for his outstanding contribution over the past years. I am extremely happy that we can further count on his expertise as Chairman of Leukocare’s Scientific Advisory Board. In his new role Andreas will coordinate the activities of the highly renowned members of the SAB and will continue to support our innovation processes in bioinformatics, analytics, and drug product development.”

Further information on Leukocare’s Executive Board members, including their CVs, can be found on the Company’s website at www.leukocare.com/who-we-are/management.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is the leading innovator for drug product development of biologics for many modalities with services specializing in drug product development tailored to the target product profile. Leukocare provides superior stabilization and optimal formulation of the drug product to increase shelf life and improve logistics, reducing risks in drug development programs. Leukocare is different from other companies in that bioinformatics and biostatistics-based approaches are used in the Design of Experiment (DoE) to explore a broader design space than conventional methods in order to find the best combination of excipients. This is achieved by synergizing in-silico methods with wet lab experiments, which reduces the number of experiments needed or the need for high throughput, resulting in the use of less drug substance and reduced development time. Our strength is that we draw on our database of over 100+ regulatory approved excipients, reducing the hurdles later in the clinic. In addition to formulation development services, Leukocare offers analytical and bioinformatics services for already in-process drug discovery and development projects. Our robust analytical expertise is applied to services ranging from particle characterization, stability and molecular integrity analysis, and long-term stability prediction to non-GMP filling for toxicology studies or molecular modeling and to help in candidate selection of drug substances.

www.leukocare.com

Contact:

Jackie Sutter
Head of Marketing, Communications,
and Digital Business
[email protected]
+49 (0) 89 7801 6650

Record changed: 2024-01-06